Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

[New anticoagulants].

T Kawasaki¹, F Hirayama

¹Institute for Drug Discovery Research, Yamanouchi Pharmaceutical Co., Ltd., Tsukuba, Ibaraki 305-8585, Japan. kawasat@yamanouchi.co.jp

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica

|February 24, 2001

Summary

New oral anticoagulants aim to overcome limitations of current drugs like heparin and coumarins, offering safer and more effective treatments for thromboembolic disorders with predictable dosing.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Frequency-Domain Multiplexing Readout with a Self-Trigger System for Pulse Signals from Kinetic Inductance Detectors.

Journal of low temperature physics·2019

Same author

Establishment of a cell panel for detecting antibodies against human platelet antigen 2b located on CD42.

Transfusion medicine (Oxford, England)·2017

Same author

Clinical utility of the basophil activation test for analysis of allergic transfusion reactions: a pilot study.

Vox sanguinis·2017

Same author

A hollow-fibre column system to effectively prepare washed platelets.

Vox sanguinis·2015

Same author

A novel mutation of the GATA site in the erythroid cell-specific regulatory element of the ABO gene in a blood donor with the Am B phenotype.

Vox sanguinis·2015

Same author

A new transfectant panel cell line-based MoAb-independent antigen capture assay system for detection of CD36 antibody.

Vox sanguinis·2014

Area of Science:

Biotechnology and pharmacology
Hematology and thrombosis research

Context:

Established anticoagulants (heparin, coumarins) have narrow therapeutic windows and unpredictable responses, leading to bleeding complications.
Clinical needs and biotechnological advances drive the development of targeted antithrombotic agents.
Limitations necessitate improved anticoagulation strategies for managing thromboembolic disorders.

Purpose:

To review the development of novel antithrombotic agents targeting specific steps in thrombogenesis.
To explore advancements in anticoagulants, including direct thrombin and factor Xa inhibitors.
To highlight the ongoing pursuit of safer, more effective oral anticoagulants.

Summary:

New anticoagulants are being developed to inactivate thrombin, factor Xa, factor IXa, or the factor VIIa/tissue factor complex.
Agents enhancing the protein C pathway and direct thrombin inhibitors are under clinical evaluation.
The focus is on developing orally active direct inhibitors of thrombin and factor Xa with consistent bioavailability.

Impact:

Future oral anticoagulants may replace coumarins for long-term thromboembolic disorder treatment.
Orally active agents could offer safer, more effective anticoagulation without intensive laboratory monitoring.
Successful development promises improved patient outcomes and reduced treatment complications.

Related Experiment Videos